- Home
- SBS vs RVMD Comparison
SBS vs RVMD Comparison
Compare SBS & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBS | RVMD |
|---|---|---|
| Founded | 1954 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4B | 15.2B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | SBS | RVMD |
|---|---|---|
| Price | $30.19 | $102.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $114.63 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.14 | $552.08 |
| P/E Ratio | $15.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.70 | $29.17 |
| 52 Week High | $30.63 | $124.49 |
Technical Indicators
Market Signals| Indicator | SBS | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 69.48 | 54.39 |
| Support Level | $23.76 | $92.76 |
| Resistance Level | N/A | $124.49 |
| Average True Range (ATR) | 0.63 | 3.62 |
| MACD | 0.02 | 0.18 |
| Stochastic Oscillator | 82.44 | 62.45 |
Price Performance
Historical ComparisonAbout SBS Companhia de saneamento Basico
Companhia De Saneamento Basico Do Estado De Sao Paulo is engaged in the provision of basic and environmental sanitation services in the Sao Paulo State and supplies treated water and sewage services on a wholesale basis. The company operates in a single segment, which is Sanitation services.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.